SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: eico20 who wrote (1896)4/29/2016 9:40:22 AM
From: mokelumne river  Read Replies (1) of 2026
 
Eman, you may be right with all of them. I have tended to discount the collusion between Pfizer and Takeda, but those guys play by different rules. I suspect all of the partners are cross-eyed that a room temp version could not be developed in the time Apricus has had. Its just not rocket science. I think I have said that before and the company still struggles with basic materials compatibility.

On your last point about a drug like Vitaros being small potatoes, that is why I thought that a Takeda would have pushed to tie up half of Europe rather than market to just one country. Sandoz and Recordati are much more the model that I thought would work. Also, I agree that a Majorelle and perhaps Ferring might be much more aggressive. Hope so.

For US marketing, they do need a major pharma to get interested and market V like a PDE5. Is that too much to expect? Allergan is big enough. You did say that Pascoe had three in the wings...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News